Literature DB >> 17495254

A review of the investigational antiarrhythmic agent dronedarone.

Mohammad J Tafreshi1, Joie Rowles.   

Abstract

Arrhythmias are a major cause of morbidity and mortality, and atrial fibrillation is the most widespread disorder of cardiac rhythm. Amiodarone is an effective antiarrhythmic agent that has been in clinical use for about 20 years. It is effective for multiple types of arrhythmias, including atrial fibrillation, and has a low incidence of cardiac adverse events, including Torsade de Pointes. It has many noncardiac adverse effects that are serious and limit its long-term use. Dronedarone is an investigational antiarrhythmic agent that is designed to have similar cardiac effects to amiodarone but with fewer adverse effects. This review presents some of the animal and human studies that evaluate the effects of dronedarone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17495254     DOI: 10.1177/1074248406299069

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  3 in total

Review 1.  Dronedarone.

Authors:  Sheridan M Hoy; Susan J Keam
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

2.  Identification of metabolic pathways and enzyme systems involved in the in vitro human hepatic metabolism of dronedarone, a potent new oral antiarrhythmic drug.

Authors:  Sylvie Klieber; Catherine Arabeyre-Fabre; Patricia Moliner; Eric Marti; Martine Mandray; Robert Ngo; Céline Ollier; Priscilla Brun; Gérard Fabre
Journal:  Pharmacol Res Perspect       Date:  2014-04-22

Review 3.  Pharmacological update: New drugs in cardiac practice: A critical appraisal.

Authors:  Rohan Magoon; Arindam Choudhury; Vishwas Malik; Ridhima Sharma; Poonam Malhotra Kapoor
Journal:  Ann Card Anaesth       Date:  2017-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.